Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models

Ovarian cancer (OVCA) inevitably acquires resistance to platinum chemotherapy and PARP inhibitors (PARPi). We show that acquisition of PARPi-resistance is accompanied by increased ATR-CHK1 activity and sensitivity to ATR inhibition (ATRi). However, PARPi-resistant cells are remarkably more sensitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyoung, Xu, Haineng, George, Erin, Hallberg, Dorothy, Kumar, Sushil, Jagannathan, Veena, Medvedev, Sergey, Kinose, Yasuto, Devins, Kyle, Verma, Priyanka, Ly, Kevin, Wang, Yifan, Greenberg, Roger A., Schwartz, Lauren, Johnson, Neil, Scharpf, Robert B., Mills, Gordon B., Zhang, Rugang, Velculescu, Victor E., Brown, Eric J., Simpkins, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381609/
https://www.ncbi.nlm.nih.gov/pubmed/32709856
http://dx.doi.org/10.1038/s41467-020-17127-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381609/
https://www.ncbi.nlm.nih.gov/pubmed/32709856
http://dx.doi.org/10.1038/s41467-020-17127-2

Ejemplares similares